GSK's Nucala study reveals more encouraging news for asthma patients

8 March 2016

Positive findings have resulted from analysis of severe asthma patients with a baseline blood eosinophil count of 150 cells/μL or above who were treated with Nucala (mepolizumab) in investigations by UK pharma giant GlaxoSmithKline (LSE: GSK).

Significant improvement in exacerbation rates was observed in patients receiving mepolizumab compared to those receiving placebo, in findings presented by GSK at the American Academy of Allergy, Asthma & Immunology annual meeting on Monday.

The greatest impact occurred in patients with higher levels of eosinophils, white blood cells which play a role in the development of asthma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK